Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT04662294 Recruiting - Multiple Myeloma Clinical Trials

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Start date: November 18, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

NCT ID: NCT04661020 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Start date: December 3, 2020
Phase: Phase 2
Study type: Interventional

A Study of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT04661007 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

J-MIND
Start date: December 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.

NCT ID: NCT04640779 Recruiting - Clinical trials for Recurrent Plasma Cell Myeloma

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Start date: February 8, 2021
Phase: Phase 1
Study type: Interventional

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their cancer (refractory) or for patients with histiocytic/dendritic cell neoplasm. Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for with non-Hodgkin or Hodgkin lymphoma, histiocytic/dendritic cell neoplasm, multiple myeloma.

NCT ID: NCT04637763 Recruiting - Lymphoma Clinical Trials

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Start date: May 26, 2021
Phase: Phase 1
Study type: Interventional

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

NCT ID: NCT04626739 Recruiting - Clinical trials for Refractory Indolent Adult Non-Hodgkin Lymphoma

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Start date: April 1, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.

NCT ID: NCT04606433 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Start date: November 4, 2020
Phase: Phase 1
Study type: Interventional

An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors.

NCT ID: NCT04603872 Recruiting - Clinical trials for Multiple Myeloma in Relapse

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

NCT ID: NCT04601831 Recruiting - Clinical trials for Non-Hodgkin Lymphoma

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Start date: December 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) patients with incomplete response (IR) to CAR T-cell therapy (CAR-T) by day 30 post-CAR-T PET/CT. We hypothesize that focal 're-priming' RT will be safe (phase I) and improve conversion to metabolic complete response (CR) by day 90 post-CAR-T PET/CT from 29% (historical control) to 58% (phase II).

NCT ID: NCT04594642 Recruiting - Follicular Lymphoma Clinical Trials

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Start date: March 2, 2021
Phase: Phase 1
Study type: Interventional

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy.